Cetuximab
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| Cetuximab?
| |
| Therapeutic monoclonal antibody | |
| Source | chimeric |
| Target | EGF receptor |
| Identifiers | |
| CAS number | |
| ATC code | L01 |
| PubChem | ? |
| DrugBank | |
| Chemical data | |
| Formula | C6484H10042N1732O2023S36 |
| Mol. mass | 145781.6 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | 114 hrs |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
|
WikiDoc Resources for Cetuximab | |
|
Articles | |
|---|---|
|
Most recent articles on Cetuximab | |
|
Media | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Cetuximab at Clinical Trials.gov Clinical Trials on Cetuximab at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Cetuximab
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Cetuximab Discussion groups on Cetuximab Directions to Hospitals Treating Cetuximab Risk calculators and risk factors for Cetuximab
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Cetuximab | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Businness | |
|
Experimental / Informatics | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-525-6884
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview
Cetuximab (marketed under the name Erbitux) is a chimeric monoclonal antibody, an epidermal growth factor receptor (EGFR) inhibitor, given by intravenous injection for treatment of metastatic colorectal cancer and head and neck cancer. Cetuximab was discovered by ImClone Systems and is distributed in North America by ImClone and Bristol-Myers Squibb, while in the rest of the world distribution is by Merck KGaA.
Cetuximab faces stiff competition from bevacizumab (Avastin), from Genentech and Roche, and from panitumumab (Vectibix), from Amgen approved by the FDA in November 2006. One of the main differences is that Cetuximab is an IgG1 antibody, and Panitumumab an IgG2 one. Their properties are not absolutely identical[3]. Cetuximab costs $30,000 for eight weeks of treatment per patient.[1]
Mode of action
Cetuximab is believed to operate by binding to the extracellular domain of the EGFR of all cells that express EGFR, which includes the subset "cancer cells", preventing ligand binding and activation of the receptor. This blocks the downstream signaling of EGFR resulting in impaired cell growth and proliferation. Cetuximab has also been shown to mediate antibody dependent cellular cytotoxicity (ADCC).
Clinical uses
Colorectal Cancer
Cetuximab is used in metastatic colon cancer and is given concurrently with the chemotherapy drug irinotecan (Camptosar®), a form of chemotherapy that blocks the effect of DNA topoisomerase I, resulting in fatal damage to the DNA of affected cells. While there remains some scientific controversy on this, assessment for EGFR expression is required for use in Colorectal Cancer, but not in Head & Neck Cancer. It is best to refer to updated Prescription Information [4].
Head and neck cancer
Cetuximab was approved by the FDA in March 2006[5] for use in combination with radiation therapy for treating squamous cell carcinoma of the head and neck (SCCHN) or as a single agent in patients who have had prior platinum-based therapy.
One of the side effects of Cetuximab therapy is the incidence of, possibly severe, acne-like rash.
ImClone insider trading scandal
- Further information: ImClone Systems#Insider trading scandal
The initial failure of ImClone Systems to prepare an acceptable FDA filing led to the infamous Martha Stewart insider trading scandal when ImClone's CEO sold ImClone shares and this information was leaked to Stewart before the FDA announced its refusal to approve the drug for public use. Martha Stewart, Samuel D. Waksal (the founder and former CEO of ImClone), and their broker were indicted, and Stewart and Waksal were sentenced to prison. ImClone shares dropped sharply in the aftermath of the insider trading scandal.
A new clinical trial and FDA filing prepared by Imclone's partner Merck KGaA ("German Merck," not to be confused with the US company of similar name) resulted in an FDA approval of the drug in 2004 for use in colon cancer.
References
External links
- FDA Erbitux (cetuximab) Information Page
- Erbitux site from Bristol-Myers Squibb, ImClone Systems, and Merck KGaA
- Anti EGFreceptor monoclonals and small molecules on the web
Chimeric monoclonal antibodies ("-xi-") | |
|---|---|
| "-tuxi-" (tumor/cancer immunotherapy) | Bavituximab, Cetuximab, Rituximab |
| "-cixi-" (cardiovascular) | Abciximab, Volociximab |
| "-lixi-" (immune system) | Basiliximab, Clenoliximab, Galiximab, Gomiliximab, Infliximab, Keliximab, Lumiliximab, Teneliximab, Vapaliximab |
| "-mexi-" (melanoma) | Ecromeximab |
| "-baxi-" (bacterial) | Pagibaximab |
de:Cetuximab fr:Cetuximab he:ארביטוקס ja:セツキシマブ
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
